Link Asia International MedTech : SUPPLEMENTAL ANNOUNCEMENT UPDATE ON FORMING THE JOINT VENTURE

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Link-Asia International MedTech Group Limited

環 亞 國 際 醫 療 科 技 集 團 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

SUPPLEMENTAL ANNOUNCEMENT

UPDATE ON FORMING THE JOINT VENTURE

Reference are made to the announcements (the ''Announcements'') issued by Link-Asia International MedTech Group Limited (the ''Company'') dated 18 March 2021 and 19 April 2021 in relation to the forming of joint venture. Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless otherwise defined.

This announcement is made to provide supplemental information on the identity of the ultimate beneficial owners of the Hanguang Technology.

FURTHER INFORMATION ON THE HANGUANG TECHNOLOGY

According to the information provided by Hanguang Technology, as at the date of this announcement, Hanguang Technology is owned as to 79% and 21% by Mr. Wang Yuhong (''Mr. Wang'') and Zhongkang Regenerative, respectively. Mr. Wang invested several biotechnology and medical related companies and took the management role. Zhongkang Regenerative is a company established in PRC with limited liability which is owned as to 40% and 60% by Dr. Sun Xiaohu (''Dr. Sun'') and Mr. Wang Xuejun, respectively. Dr. Sun was an independent non-executive Director of the Company from 6 January 2021 to 19 April 2021, while Mr. Wang Xuejun has extensive experience in the stem cell industry, whose biography can be found in the announcement published by the Company on 18 March 2021.

To the best of knowledge, information and belief of the Directors having made all reasonable inquiries, Mr. Wang, and Mr. Wang Xuejun are third parties independent of the Company and its connected persons (as defined in the Listing Rules).

On behalf of the Board

Link-Asia International MedTech Group Limited

Lin Dailian

Chairman and executive Director

Hong Kong, 23 April 2021

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Mr. Xia Xiaobing as executive Directors; Mr. Li Huiwu and Mr. Yang Weidong as independent non-executive Directors.